Filing Flows › Kyntra Bio (KYNB) › Recalls, complaints & regulation
Kyntra Bio (KYNB): clinical trials
Kyntra Bio (KYNB) beyond its filings: 2 active clinical trials.
Kyntra Bio's latest quarter
Kyntra Bio, Q1 2026: revenue $3.7M (+36% year over year), operating margin -369.7%, net loss $15.2M, operating cash flow −$13.9M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Kyntra Bio have?
2 active studies on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.